• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Does circulating DNA tumor fraction add value to prostate-specific antigen in metastatic castration-resistant prostate cancer?

作者信息

Sternberg Cora N, Hussain Maha

机构信息

Englander Institute for Precision Medicine, New York, NY, USA.

Department of Hematology/Oncology, Weill Cornell Medicine, Sandra and Edward Meyer Cancer Center, New York-Presbyterian, New York, NY, USA.

出版信息

Transl Cancer Res. 2025 May 30;14(5):2536-2538. doi: 10.21037/tcr-2025-295. Epub 2025 May 13.

DOI:10.21037/tcr-2025-295
PMID:40530150
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12170075/
Abstract
摘要

相似文献

1
Does circulating DNA tumor fraction add value to prostate-specific antigen in metastatic castration-resistant prostate cancer?循环DNA肿瘤分数对转移性去势抵抗性前列腺癌中的前列腺特异性抗原有附加价值吗？
Transl Cancer Res. 2025 May 30;14(5):2536-2538. doi: 10.21037/tcr-2025-295. Epub 2025 May 13.
2
Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer.循环肿瘤 DNA 评估用于治疗监测在转移性去势抵抗性前列腺癌中增加了 PSA 的价值。
Clin Cancer Res. 2024 Sep 13;30(18):4115-4122. doi: 10.1158/1078-0432.CCR-24-1096.
3
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.基于循环肿瘤 DNA 改变的临床和基因组分析在转移性激素敏感型和去势抵抗性前列腺癌中的应用。
EBioMedicine. 2020 Apr;54:102728. doi: 10.1016/j.ebiom.2020.102728.
4
Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study.血浆循环肿瘤 DNA 片段对四种常见癌症类型的预后价值：一项真实世界研究结果。
Ann Oncol. 2023 Jan;34(1):111-120. doi: 10.1016/j.annonc.2022.09.163. Epub 2022 Oct 5.
5
Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?转移性去势抵抗性前列腺癌中的治疗生物标志物：状态重要吗？
Crit Rev Clin Lab Sci. 2024 May;61(3):178-204. doi: 10.1080/10408363.2023.2266482. Epub 2023 Oct 26.
6
Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer.早期治疗中循环肿瘤 DNA 分数的变化与转移性去势抵抗性前列腺癌对恩杂鲁胺或阿比特龙的反应
Clin Cancer Res. 2023 Aug 1;29(15):2835-2844. doi: 10.1158/1078-0432.CCR-22-2998.
7
Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer.循环肿瘤DNA的低通量全基因组测序在转移性去势抵抗性前列腺癌中的预后价值
Clin Chem. 2023 Apr 3;69(4):386-398. doi: 10.1093/clinchem/hvac224.
8
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer.转移性去势抵抗性前列腺癌中转移模式的改变与循环肿瘤DNA的动态变化相关。
Oncologist. 2025 May 8;30(5). doi: 10.1093/oncolo/oyaf107.
9
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.通过对循环肿瘤 DNA 进行低深度全基因组测序来阐明治疗过程中的前列腺癌行为。
Eur Urol. 2021 Aug;80(2):243-253. doi: 10.1016/j.eururo.2021.05.030. Epub 2021 Jun 5.
10
Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.循环肿瘤 DNA 作为阿比特龙治疗后转移性去势抵抗性前列腺癌恩扎卢胺治疗反应的预测因子。
Cancer Treat Res Commun. 2020;24:100193. doi: 10.1016/j.ctarc.2020.100193. Epub 2020 Jul 14.

本文引用的文献

1
Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer.循环肿瘤 DNA 评估用于治疗监测在转移性去势抵抗性前列腺癌中增加了 PSA 的价值。
Clin Cancer Res. 2024 Sep 13;30(18):4115-4122. doi: 10.1158/1078-0432.CCR-24-1096.
2
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.晚期前列腺癌中血浆 ctDNA 片段的预测和液体活检的预后意义。
Nat Commun. 2024 Feb 28;15(1):1828. doi: 10.1038/s41467-024-45475-w.
3
Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer.
早期治疗中循环肿瘤 DNA 分数的变化与转移性去势抵抗性前列腺癌对恩杂鲁胺或阿比特龙的反应
Clin Cancer Res. 2023 Aug 1;29(15):2835-2844. doi: 10.1158/1078-0432.CCR-22-2998.
4
Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study.血浆循环肿瘤 DNA 片段对四种常见癌症类型的预后价值：一项真实世界研究结果。
Ann Oncol. 2023 Jan;34(1):111-120. doi: 10.1016/j.annonc.2022.09.163. Epub 2022 Oct 5.
5
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.阿替利珠单抗联合恩扎卢胺对比单独恩扎卢胺治疗转移性去势抵抗性前列腺癌：一项随机、3 期临床试验。
Nat Med. 2022 Jan;28(1):144-153. doi: 10.1038/s41591-021-01600-6. Epub 2022 Jan 10.
6
Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies.鉴定肿瘤组织来源的DNA甲基化生物标志物用于液体活检中转移性去势抵抗性前列腺癌的检测及治疗反应评估
Mol Cancer. 2022 Jan 3;21(1):7. doi: 10.1186/s12943-021-01445-0.
7
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.转移性去势抵抗性前列腺癌中循环肿瘤细胞AR-V7及紫杉烷与激素治疗结局的前瞻性多中心研究
JCO Precis Oncol. 2020 Oct 28;4. doi: 10.1200/PO.20.00200. eCollection 2020.
8
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.FoundationOne Liquid CDx 的临床和分析验证，一种新型的基于 324 个基因 cfDNA 的用于实体瘤来源的癌症的全面基因组分析检测方法。
PLoS One. 2020 Sep 25;15(9):e0237802. doi: 10.1371/journal.pone.0237802. eCollection 2020.